Metformin doesn't improve breast cancer survival in diabetes patients

08/24/2011 | Medscape (free registration)

Metformin-treated patients with diabetes who were on adjuvant chemotherapy for triple-negative breast cancer had an overall survival rate of 67%, while those in the nontreated and no-diabetes groups had 69% and 66% OS rates respectively, a study in Cancer found. The findings, however, did suggest a lower risk of developing distant metastasis in diabetic patients taking metformin compared with nondiabetic patients, the researchers said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY